| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.053 | 0.4 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.4 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.4 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.052 | 0.4 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | -0.065 | 0.4 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.4 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |